[{"id":"54aedf1b-8639-4b4b-b9aa-25ad0d19b92e","acronym":"PANDA-VAC","url":"https://clinicaltrials.gov/study/NCT04266730","created_at":"2021-01-18T20:43:54.453Z","updated_at":"2024-07-02T16:35:05.381Z","phase":"Phase 1","brief_title":"Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab","source_id_and_acronym":"NCT04266730 - PANDA-VAC","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PANDA-VAC"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 08/22/2024","start_date":" 08/22/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2033","study_completion_date":" 06/01/2033","last_update_posted":"2024-05-07"}]